CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
S0309 | SWOG | Myeloma Specimen Repository Protocol Ancillary | Adult CIRB - Late Phase Emphasis | Completed |
S2101 | SWOG | Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study | Adult CIRB - Late Phase Emphasis | Available to Open |
S1934 | SWOG | NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
S1609 | SWOG | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
S1900C | SWOG | A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LungMAP Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
S0931 | SWOG | EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy; A Phase III Study | Adult CIRB - Late Phase Emphasis | Available to Open |
S1207 | SWOG | Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy | Adult CIRB - Late Phase Emphasis | Available to Open |
S2210 | SWOG | A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations | Adult CIRB - Late Phase Emphasis | Available to Open |
S1505 | SWOG | A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
S0221 | SWOG | Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC; Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |